DU‐145 and PC‐3 human prostate cancer cell lines express androgen receptor: Implications for the androgen receptor functions and regulation

The majority of human prostate cancer cell lines, including the two “classical” cell lines DU‐145 and PC‐3, are reported to be androgen receptor (AR)‐negative. However, other studies have provided evidence that the DU‐145 and PC‐3 cell lines express AR mRNA. These contradictory observations prompted us to investigate whether DU‐145 and PC‐3 cell lines express the androgen receptor. Using antipeptide antibodies directed against three distinct regions of the human AR protein and an improved method to detect AR protein in immunoblotting, we report that DU‐145 and PC‐3 cell lines express AR protein. We found that the relative levels of the AR mRNA and protein that were detected in DU‐145 and PC‐3 cell lines were lower than the LNCaP, an AR‐positive cell line. Moreover, the antibody directed against the non‐variant region (amino acids 299–315), but not the variant N‐ or C‐terminal region (amino acids 1–20 and 900–919, respectively) of the human AR protein, detected the expression of AR in all prostate cancer cell lines. Notably, treatment of these cell lines with dihydrotestosterone (DHT) resulted in measurable increases in the AR protein levels and considerable nuclear accumulation. Although, treatment of DU‐145 and PC‐3 cells with DHT did not result in stimulation of the activity of an AR‐responsive reporter, knockdown of AR expression in PC‐3 cells resulted in decreases in p21CIP1 protein levels, and a measurable decrease in the activity of the p21‐luc‐reporter. Our observations demonstrate the expression of AR protein in DU‐145 and PC‐3 prostate cancer cell lines.

[1]  M. Shen,et al.  Mouse models of prostate carcinogenesis. , 2002, Trends in genetics : TIG.

[2]  Tetsurou Matsumoto,et al.  Different expression of androgen receptor coactivators in human prostate. , 2001, Urology.

[3]  A. Brinkmann,et al.  Phosphotryptic peptide analysis of the human androgen receptor: detection of a hormone-induced phosphopeptide. , 1995, Biochemistry.

[4]  D. Neal,et al.  Expression of RAC 3, a steroid hormone receptor co-activator in prostate cancer , 2001, British Journal of Cancer.

[5]  John M S Bartlett,et al.  The androgen receptor and signal‐transduction pathways in hormone‐refractory prostate cancer. Part 1: modifications to the androgen receptor , 2005, BJU international.

[6]  K. Nakashiro,et al.  Androgen receptor expression in androgen‐independent prostate cancer cell lines , 2001, The Prostate.

[7]  G. Stamp,et al.  Phenotypic and genotypic characterization of commonly used human prostatic cell lines , 2000, BJU international.

[8]  G. Mills,et al.  Androgen-induced inhibition of cell proliferation in an androgen-insensitive prostate cancer cell line (PC-3) transfected with a human androgen receptor complementary DNA. , 1993, Cancer research.

[9]  J. Trapman,et al.  The androgen receptor in prostate cancer. , 1996, Pathology, research and practice.

[10]  G. Coetzee,et al.  Contribution of the Androgen Receptor to Prostate Cancer Predisposition and Progression , 2004, Cancer and Metastasis Reviews.

[11]  C. Korch,et al.  Molecular characterization of human prostate carcinoma cell lines , 2003, The Prostate.

[12]  G. Stark,et al.  How cells respond to interferons. , 1998, Annual review of biochemistry.

[13]  M. Tsai,et al.  Androgen regulation of the cyclin-dependent kinase inhibitor p21 gene through an androgen response element in the proximal promoter. , 1999, Molecular endocrinology.

[14]  G. Jenster,et al.  Changes in the abundance of androgen receptor isotypes: effects of ligand treatment, glutamine-stretch variation, and mutation of putative phosphorylation sites. , 1994, Biochemistry.

[15]  J. Herman,et al.  Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate cancer cells. , 1998, Cancer research.

[16]  E. Gelmann,et al.  Molecular biology of the androgen receptor. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  T. Visakorpi,et al.  Alterations of androgen receptor in prostate cancer , 2004, The Journal of Steroid Biochemistry and Molecular Biology.

[18]  G. Coetzee,et al.  PC‐3 cells with enhanced androgen receptor signaling: A model for clonal selection in prostate cancer , 2004, The Prostate.

[19]  P. Lengyel,et al.  Interferon action: cytoplasmic and nuclear localization of the interferon-inducible 52-kD protein that is encoded by the Ifi 200 gene from the gene 200 cluster. , 1993, Journal of interferon research.

[20]  H. Klocker,et al.  DNA sequence of the androgen receptor in prostatic tumor cell lines and tissue specimens assessed by means of the polymerase chain reaction , 1993, The Prostate.

[21]  T Visakorpi,et al.  Molecular genetics of prostate cancer. , 2001, Annals of medicine.

[22]  J. Melamed,et al.  Cell-specific Regulation of Androgen Receptor Phosphorylation in Vivo* , 2005, Journal of Biological Chemistry.

[23]  G. Prins,et al.  Molecular biology of the androgen receptor. , 2000, Mayo Clinic proceedings.

[24]  D. Horsfall,et al.  Evidence for a novel mechanism of androgen resistance in the human prostate cancer cell line, PC-3 , 1995, Steroids.

[25]  H. Klocker,et al.  Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor and epidermal growth factor. , 1995, European urology.

[26]  G. Sica,et al.  Natural β-Interferon and Androgen Receptors in Prostatic Cancer Cells , 1991 .

[27]  C. Heinlein,et al.  Androgen receptor (AR) coregulators: an overview. , 2002, Endocrine reviews.

[28]  Bernhard O. Palsson,et al.  Cancer cell lines , 1999 .

[29]  A. Fattorossi,et al.  Androgen receptors and hormone sensitivity of a human prostatic cancer cell line (PC-3) are modulated by natural beta-interferon , 2004, Urological Research.

[30]  N. Weigel,et al.  Repressors of Androgen and Progesterone Receptor Action* , 2003, Journal of Biological Chemistry.

[31]  Z. Hall Cancer , 1906, The Hospital.

[32]  A. Atala,et al.  Detection of human androgen receptor mRNA expression abnormalities by competitive PCR. , 1994, DNA and cell biology.

[33]  H. Klocker,et al.  Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. , 1998, Cancer research.

[34]  R. Johnstone,et al.  Role of IFI 16, a member of the interferon-inducible p200-protein family, in prostate epithelial cellular senescence , 2003, Oncogene.